Stockwinners Market Radar for August 10, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:26 EDT Cathie Wood's ARK Investment bought 155K shares of 2U today

19:22 EDT Cadence Design director sells $2.03M in common stock - In a regulatory filing, Cadence Design disclosed that its director Vincentelli Sangiovanni sold 8.8K shares of common stock on August 8th in a total transaction size of $2.03M.

18:17 EDT AptarGroup director Fotiades sells 7,940 common shares - In a regulatory filing, AptarGroup director George Fotiades disclosed the sale of 7,940 common shares of the company on August 10 at a price of $122.0101 per share.

18:06 EDT Avidity Biosciences granted FDA Orphan Drug Designation in DMD - Avidity Biosciences' antibody oligonucleotide conjugate was granted orphan designation by the FDA in the treatment of Duchenne Muscular Dystrophy. Reference Link

17:46 EDT Akebia announces late filing of Q2 earnings - Akebia has filed with the SEC a Form 12b-25 Notification of Late Filing with regard to its Quarterly Report on Form 10Q for the quarter ended June 30. Through the course of preparing its Q2financial statements, Akebia identified certain accounting errors relating to recording and reporting of return reserves for Auryxia . Akebia does not currently anticipate that the correction of the accounting errors will impact Akebia's previously issued 2023 Auryxia net product revenue guidance of $175M-$180M. In addition, based on its current operating plan, Akebia believes that its cash resources as of June 30 and revenues from Auryxia will be sufficient to allow Akebia to fund its current operating plan through at least the next twelve months from the date of this filing. The delay in filing will not affect Akebia's ability to serve existing or new patients. Akebia continues to expect to resubmit its New Drug Application for vadadustat as a treatment for anemia due to chronic kidney disease in adult patients on dialysis by the end of this quarter.

17:24 EDT Samsara CEO sells $2.2M in common stock - In a regulatory filing, Samsara disclosed that its CEO Sanjit Biswas sold 89.8K shares of common stock on August 8th in a total transaction size of $2.19M.

17:06 EDT View Inc. regains compliance with Nasdaq - View, Inc. announced that it has received a confirmation letter from Nasdaq affirming that the company is now in compliance with Listing Rule 5450. View is now in compliance with all applicable listing standards. View's common stock will continue to be listed on The Nasdaq Stock Market and Nasdaq has closed this matter.

17:04 EDT Minim announces CFO Dustin Tacker has resigned effective August 4 - Minim (MINM), the creator of intelligent networking products under the Motorola brand (MSI), announced that Dustin Tacker has resigned from his role as Chief Financial Officer, effective August 4, 2023 to pursue new career opportunities. His resignation is not the result of any dispute or disagreement with the company. Mr. Tacker is committed to an orderly transition of his duties and will stay with the company until the earlier of August 31 or when the Company and Mr. Tacker agree.

17:02 EDT Genfit publishes new data on clinical performance of NIS2+ in older patients - Genfit announced the publication of new data on the clinical performance of NIS2+ in older patients, for the detection of at-risk nonalcoholic steatohepatitis, or NASH, in Hepatology Communications. In conjunction with Labcorp, a global leader of innovative and comprehensive laboratory services, data reported in the manuscript is the first to show and compare the clinical performance of NIS4(R) and its recently developed and improved upgrade NIS2+ in a population of older adults with well-established biomarker panels: FIB-4, NFS, ELF and ALT. While previously published data showed that NIS2+(TM) had a high overall clinical performance for the detection of at-risk NASH achieving an AUROC2 of 0.81 in a large study population, the Centers for Medicare & Medicaid Services, or CMS, in the US requires peer-reviewed, published data showing that tests, that will be used for patient management, have high assay performance in patients who are greater than or equal to65 years of age. Results of this study showed the clinical performance of NIS2+ was superior to other tests for the diagnosis of at-risk NASH in patients greater than or equal to65 years of age, greatly assisting with CMS reimbursement efforts. These data support the clinical value of this blood-based test for the diagnosis of at-risk NASH in older adults who would benefit from intensive lifestyle or therapeutic interventions.

17:01 EDT Parsons selected for $109M classified contract from U.S. Cyber Command - Parsons announced that the company has been selected by United States Cyber Command CYBERCOM to continue support previously provided under the command, control, communications, computers, and capabilities development C4CD and C4CD Bridge contracts. The $109M classified contract includes a one-year base period plus four one-year option periods. "Our unmatched technical talent and disruptive, warfighter-focused capabilities enhance mission effectiveness for CYBERCOM as they continue defending and advancing national security interests," said Mike Kushin, president of Parsons' Defense and Intelligence sector. "We are proud to continue our ongoing CYBERCOM support, with a focus on the J9 Acquisition and Technology Directorate mission set." Parsons operates in every aspect of the all-domain battlespace and addresses emerging threats by fusing technologies across the now-connected warfighting domains and incorporates information operations, intelligence, data analytics, electronic warfare, multi-echelon command and control, and kinetic operations into a unified approach.

16:56 EDT Joint Corp. reports Q2 system-wide sales $120.1M, up 13% - "In the second quarter of 2023, we posted system-wide sales growth of 13% year-over-year supported by our ongoing franchise license sales, clinic openings, and new patient acquisitions, even during this environment of continued economic uncertainty," said Peter Holt, president and CEO of The Joint Corp. "Continually striving to do better, we are enhancing national brand building and implementing additional digital, automated and traditional marketing strategies to drive new patient acquisitions.

16:49 EDT U.S. Bancorp CFO Dolan sells 26,000 common shares - In a regulatory filing, U.S. Bancorp vice chair and CFO Terrance Dolan disclosed the sale of 26,000 common shares of the company on August 8 at a price of $39.753 per share.

16:41 EDT Salarius Pharmaceuticals explores strategic alternatives, begins cost savings - "It was an exceptionally difficult decision to initiate our cost-savings plans and explore strategic alternatives in light of the promising early seclidemstat Ewing sarcoma clinical data, seclidemstat hematological clinical data and the recent FDA clearance to begin the SP-3164 Phase 1 trial. Unfortunately, we believe the current public financial markets make it extremely challenging to raise sufficient capital to continue meaningful clinical development activities on our own," concluded Mr. Arthur. The Company is conducting a comprehensive review of strategic alternatives focused on maximizing shareholder value including, but not limited to, an acquisition, merger, reverse merger, divestiture of assets, licensing or other strategic transactions involving the Company. However, there is no set timetable for this process and there can be no assurance that this process will result in the Company pursuing a transaction or that any transaction, if pursued, will be completed on attractive terms. If the Company is unable to complete a transaction it may be necessary to seek other alternatives for restructuring and resolving its liabilities, including an orderly wind-down. Salarius does not expect to disclose developments with respect to this process unless and until the evaluation of strategic alternatives has been completed or the Board of Directors has concluded that disclosure is appropriate or legally required. In connection with the evaluation of strategic alternatives and in order to extend its resources, Salarius is implementing a cost-savings plan that includes a reduction in workforce by over 50% of its positions, with remaining employees focusing primarily on limited drug-development activities, completing the U.S. Food and Drug Administration (FDA) process to determine the clinical trial registration requirements for the seclidemstat Ewing sarcoma program and supporting the exploration of strategic alternatives.

16:29 EDT Cano Health pursuing sales process, exiting operations in several markets - Cano Health is pursuing a comprehensive process to identify and evaluate interest in a sale of the company, or all or substantially all of its assets, consistent with the terms and conditions of the 2023 Side-Car Amendment. The company has engaged advisors to assist in the process. The company has not set a timetable for the conclusion of this process. In addition, the company has made progress in its assessment of its non-core assets. So far, Cano Health plans to exit operations in California, New Mexico and Illinois by the fall of 2023. As of June 30, , these geographies accounted for approximately 5,000 total members and 17 medical centers across the three states. The company also plans to exit its Puerto Rico operations by January 1, 2024, which has approximately 8,000 members cared for by affiliates. The company is continuing to assess the divestiture of other non-core assets and business lines, while focusing on improving operations for its Medicare Advantage and ACO REACH businesses in its remaining core geographies. Proceeds from any non-core divestitures would be utilized for general corporate purposes and debt repayment. Cano Health has also developed a plan to further restructure its operations to improve efficiency and reduce costs. In Q3, the company expects to reduce its workforce by approximately 700 employees, or 17%. These actions are expected to yield approximately $50M of annualized cost reductions beginning in Q3 and through the end of 2024. The company expects to record a restructuring charge in Q3 of approximately $4M, the majority of which will be paid in 2023 and a lesser amount in 2024. The company's current liquidity as of August 9 was approximately $101M, consisting of cash and cash equivalents. The company currently believes that this amount of liquidity is not sufficient to cover its uses for the next 12 months. Management has concluded that there is substantial doubt about the company's ability to continue as a going concern within one year.

16:26 EDT Genasys expects FY23 to be down from FY22 - Software bookings are tracking ahead of internal expectations. Recent competitive wins and our brand relaunch earlier this week provide added confidence in our solutions and go-to-market approach. While our hardware pipeline continues to grow, delays in closing associated orders continue to challenge this year's revenues. As a result, we are realigning our resources accordingly. Genasys expects Fiscal 2023 to be down from Fiscal 2022 with fourth quarter revenues approximately 5% below the prior quarter.

16:14 EDT AN2 Therapeutics expects cash to fund operations through end of 2024 - On June 26, 2023, the Company sold an aggregate of 2,502,000 shares of the Company's common stock at a purchase price of $8.00 per share under its existing at-the-market offering. This resulted in aggregate gross proceeds to the Company of approximately $20 million. The Company expects that current cash, cash equivalents and investments of $95.3 million at June 30, 2023, will be sufficient to fund its operating expenses through the expected data readout of the Phase 2 portion of its pivotal Phase 2/3 trial in treatment-refractory MAC lung disease and through the end of 2024.

16:09 EDT Maxeon Solar choses Albuquerque, New Mexico for manufacturing expansion - Maxeon Solar Technologies announced it has chosen Albuquerque, New Mexico, as the location for its first U.S. manufacturing expansion. The new world-class, 3-gigawatt facility will be designed to produce latest-generation TOPCon PV-silicon cell technology and the company's proprietary shingled-cell Performance Line solar modules to meet rapidly growing demand for domestically produced solar panels. The new plant is planned to serve both the Utility Scale Power Plant market and Distributed Generation rooftop applications. The total investment of the project is expected to be over $1 billion, and is subject to a successful financial close under the U.S. Department of Energy's Title 17 Clean Energy Financing Program. Maxeon is currently in the due diligence stage of its loan application and site selection is an important milestone in completing this process with DOE's Loan Programs Office. DOE's invitation into the due diligence and term sheet negotiation process is not an assurance that DOE will issue a loan guarantee, nor that the terms and conditions of a loan guarantee will align with terms proposed by the applicant. The Maxeon plant is expected to be the first large-scale PV cell and panel manufacturing in New Mexico, and its planned capacity is approximately double the size of the largest silicon solar manufacturing facility currently operating in the U.S. Maxeon expects to begin construction in the first quarter of 2024, with factory ramp-up to commence in 2025. Maxeon has selected a 160-acre site located in the community of Mesa Del Sol, and is designing the complex to include solar cell fabrication, panel assembly, a warehouse, and administrative offices. Once complete, Maxeon estimates the new facility will create up to 1,800 jobs, including highly skilled manufacturing and engineering jobs, and produce millions of solar panels each year for the U.S. market. The New Mexico facility expands Maxeon's global manufacturing footprint, which currently includes plants in Mexico, Malaysia and the Philippines.Due to strong customer demand and the planned availability of sufficient infrastructure at the Mesa Del Sol site, Maxeon is currently evaluating plans to upsize the scale of its U.S. manufacturing operation by approximately 50% to a nameplate capacity of 4.5 GW. A final decision regarding plant capacity is expected later this year.

16:08 EDT Shattuck Labs sees cash as sufficient to fund operations through year-end 2024 - "Shattuck believes its cash and cash equivalents and investments will be sufficient to fund its operations through year-end 2024, beyond results from its Phase 1 clinical trials of SL-172154. This cash runway guidance is based on the company's current operational plans and excludes any additional capital that may be received, proceeds from business development transactions, and/or additional costs associated with clinical development activities that may be undertaken," the company stated.

16:06 EDT Ameresco acquires energy resilience project in Los Alamitos, CA - Ameresco "announced its acquisition of an energy resilience project that combines a microgrid, solar panels and a battery energy storage system at Joint Forces Training Base (JFTB) in Los Alamitos, California. Ameresco acquired the clean energy asset from Bright Canyon Energy, who was the developer of the microgrid. The work deployed at JFTB included the development and construction of a microgrid designed to provide the military base with 100% backup power in emergencies to support the Army and California National Guard, and generate clean, renewable solar energy for the surrounding community during normal operations. The project will increase energy resilience for JFTB and Southern California by adding locally generated carbon-free renewable electricity to the grid. The microgrid is designed to provide 31.5 megawatts (MW) of solar-generated electricity capacity and includes a 20 MW/40 megawatt-hour battery energy storage system, microgrid controls and 3MW of backup generators, which is equivalent to powering a residential area of more than 5,000 homes."

16:02 EDT Vista Outdoor to rebrand as The Kinetic Group - Vista Outdoor announced its new name and identity that will be effective following the planned spinoff of Vista Outdoor's Outdoor Products business. Post-spin, Vista Outdoor will be rebranded as The Kinetic Group, a name that surfaced among employees during the naming process and represents the energy behind the company and its leading ammunition brands. The Kinetic Group will trade on the New York Stock Exchange under the stock ticker "HUNT," and the brand will feature original logo artwork of a North American ram.

15:14 EDT Medtech Acquisition Corp trading resumes

15:09 EDT Medtech Acquisition Corp trading halted, volatility trading pause

14:03 EDT Bethesda announces, releases 'Quake II' remaster - Microsoft's (MSFT) Bethesda announced that an enhanced version of "Quake II" is out Thursday for Xbox, PlayStation (SONY), PC, and Nintendo Switch (NTDOY). The previously unannounced game, which includes visual enhancements, new content, and online multiplayer, is also available day one on Microsoft's Game Pass subscription service. Reference Link

13:08 EDT Ford learned from supplier about vulnerability in SYNC 3 infotainment system - Ford issued the following statement: "Ford takes cyber security seriously and regularly works with security researchers, suppliers and other vehicle manufacturers to protect our customers, products and enterprise.Ford learned from a supplier that a security researcher discovered a vulnerability in the Wi-Fi software driver supplied for use in the SYNC 3 infotainment system available on some Ford and Lincoln vehicles. Immediately, and in collaboration with them, we began developing and validating measures to address the vulnerability. To date, we've seen no evidence that this vulnerability has been exploited, which would likely require significant expertise and would also include being physically near an individual vehicle that has its ignition and Wi-Fi setting on. Our investigation also found that if this vulnerability was exploited, however unlikely, it would not affect the safety of vehicle occupants, since the infotainment system is firewalled from controls like steering, throttling and braking.Soon, Ford will issue a software patch online for download and installation via USB. In the interim, customers who are concerned about the vulnerability can simply turn off the Wi-Fi functionality through the SYNC 3 infotainment system's Settings menu. Customers can also find out online if their vehicles are equipped with SYNC 3." Reference Link

13:05 EDT RTX receives contract award to support DARPA's 'In The Moment' program - RTX's BBN division received a contract award to support DARPA's "In The Moment" program. ITM aims to develop the foundations needed for algorithms that are trusted to independently make decisions in scenarios like mass casualty triage and disaster relief, where complex and rapid decisions are needed in dynamic situations where there is often no human consensus and no clear right answer.

13:00 EDT Update on off-the-shelf program should come soon, Marker chief says

13:00 EDT Marker CEO expects some patient data readout for MT-601 study by year-end

12:45 EDT Virgin Galactic announces completion of first private astronaut flight - Virgin Galactic announced the completion of its first private astronaut flight, "Galactic 02." The company said: "The mission achieved multiple historic milestones, showcasing how Virgin Galactic spaceflights are broadening access to space for a diverse, global community of astronauts... The company will now proceed with post-flight inspections and analysis in preparation for the next commercial space mission, 'Galactic 03,' which is planned for September in a continuation of Virgin Galactic's monthly flight cadence."

12:00 EDT Enerflex falls -17.0% - Enerflex is down -17.0%, or -$1.36 to $6.62.

12:00 EDT FutureFuel falls -22.6% - FutureFuel is down -22.6%, or -$2.23 to $7.65.

12:00 EDT Yeti rises 20.8% - Yeti is up 20.8%, or $8.21 to $47.77.

11:51 EDT Evolve Transition Infrastructure LP trading resumes

11:39 EDT FDA grants accelerated approval of Janssen's Talvey - The Janssen Pharmaceutical Companies of Johnson & Johnson announced earlier that the U.S. Food and Drug Administration has granted accelerated approval of Talvey, or talquetamab-tgvs, a "first-in-class" bispecific antibody for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. "This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication is contingent upon verification and description of clinical benefit in confirmatory trial(s)," the company noted.

11:17 EDT Organogenesis slides after reporting Q2 results, removing FY guidance - Shares of Organogenesis are under pressure on Thursday after the wound-care products manufacturer reported quarterly results and withdrew its forecast for the fiscal year. The company reported Q2 2023 revenue of $117.3M versus consensus of $118.2M, and down $4.1M from Q2 2022. Organogenesis' also said that it was withdrawing its previously announced fiscal year 2023 guidance, originally issued on May 10, 2023, "due to the uncertainty resulting from the potential impact of the recently published local coverage determinations from Novitas, First Coast Services and CGS to limit coverage for treatment of diabetic foot ulcers and venous leg ulcers to include only Apligraf and Dermagraft. The company is currently unable to predict the impact that the recently published local coverage determinations will have on its financial position and operating results." In Thursday morning trading, shares of Organogenis have dropped almost 25% to $2.55.

11:07 EDT eXp Realty exceeds 1,000 agents across South Africa - eXp Realty has exceeded 1,000 agents across South Africa, representing an over 74% increase from the 574 total agent count in July 2022.

11:02 EDT IBM completes acquisition of Apptio - IBM announced it has completed its acquisition of Apptio Inc. after receiving all required regulatory approvals. "The acquisition gives clients the ability to derive additional value through the powerful combination of Apptio and IBM... Starting immediately, clients can leverage the early integration between Apptio and IBM through their Cloudability and Turbonomic offerings. This is an important first step as IBM looks to drive significant synergy across several key growth areas, including automation, Red Hat, IBM Consulting, and IBM's broader AI portfolio," the company stated. "The combination of Apptio products and IBM's IT automation portfolio will give businesses a 360-degree technology management platform they can use to optimize and automate decisions across their IT landscapes. We are bringing together market-leading and best-in-class solutions to continue to reshape IT from a cost center to a true competitive advantage, powered by automation and AI," said Rob Thomas, Senior Vice President, Software and Chief Commercial Officer, IBM.

10:03 EDT Black Spade Acquisition investors approve VinFast combination - VinFast Auto Ltd. and Black Spade Acquisition Co announced that their previously announced business combination was approved at an extraordinary general meeting of Black Spade's shareholders on August 10, 2023. Complete official results of the vote will be included in a current report on Form 8-K to be filed by Black Spade with the U.S. Securities and Exchange Commission. The Business Combination is expected to close on August 14, 2023. Upon such closing, VinFast will remain as the combined company, and its ordinary shares and warrants are expected to begin trading on the Nasdaq Stock Market LLC under the new ticker symbol "VFS" on or around August 15, 2023.

10:01 EDT Rio Tinto to build solar power plant in Canada's North - Rio Tinto's Diavik Diamond Mine will build the largest solar power plant across Canada's territories, featuring over 6,600 solar panels that will generate approximately 4,200 megawatt-hours of carbon-free electricity annually for the mine. The solar power plant will provide up to 25% of Diavik's electricity during closure work that will run until 2029, with commercial production from the operation expected to end in early 2026, the company said in a statement. Construction will start in coming weeks and the solar power plant will be fully operational in the first half of 2024, Rio added.

10:00 EDT FutureFuel falls -17.5% - FutureFuel is down -17.5%, or -$1.73 to $8.15.

10:00 EDT Holley rises 18.9% - Holley is up 18.9%, or $1.18 to $7.38.

10:00 EDT Capri Holdings rises 56.5% - Capri Holdings is up 56.5%, or $19.57 to $54.18.

09:47 EDT U.S. Steel, Google Cloud announces collaboration for generative AI - United States Steel Corporation (X) and Google Cloud (GOOG) announced a new collaboration to build applications using Google Cloud's generative artificial intelligence technology to drive efficiencies and improve employee experiences in the largest iron ore mine in North America. The first gen AI-driven application that U. S. Steel will launch is called MineMind which aims to simplify equipment maintenance by providing optimal solutions for mechanical problems, saving time and money, and ultimately improving productivity. Underpinned by Google Cloud's AI technology like Document AI and Vertex AI, MineMind is expected to not only improve the maintenance team's experience by more easily bringing the information they need to their fingertips, but also save costs from more efficient use of technicians' time and better maintained trucks. The initial phase of the launch will begin in September and will impact more than 60 haul trucks at U. S. Steel's Minnesota Ore Operations facilities, Minntac and Keetac.

09:47 EDT Sunlands Online falls -14.3% - Sunlands Online is down -14.3%, or -93c to $5.58.

09:47 EDT Holley rises 15.3% - Holley is up 15.3%, or 95c to $7.16.

09:47 EDT Capri Holdings rises 57.4% - Capri Holdings is up 57.4%, or $19.86 to $54.47.

09:45 EDT electroCore, Inc. trading resumes

09:40 EDT electroCore, Inc. trading halted, volatility trading pause

09:37 EDT Knightscope announces three new sales - Knightscope announced new sales for a third party logistics provider in the Midwest; a Central-US regional transit authority; and a country club in the Northeast.

09:36 EDT Seneca Foods trading halted, volatility trading pause

09:34 EDT Certara trading halted, volatility trading pause

09:26 EDT Real Brokerage promotes Jenna Rozenblat to Chief Operating Officer - The Real Brokerage announced the promotion of Jenna Rozenblat to Chief Operating Officer. In this role, Rozenblat will be responsible for overseeing Real's day-to-day operations, implementing strategies to enhance efficiency and ensuring the execution of the company's vision to build a technology platform that simplifies the process of buying and selling homes for agents and their clients.

09:16 EDT Intuitive Machines says U.S. GAO validates NASA's $719M OMES III Award - Intuitive Machines (LUNR) welcomes the recent U.S. Government Accountability Office's decision affirming NASA's thorough evaluation of the OMES III proposals, resulting in the award of the five-year contract to Space & Technology Solutions, the DBA for Space Network Solutions LLC, a joint venture led by Intuitive Machines with KBR (KBR). The OMES III Contract is a cost-plus-fixed-fee indefinite-delivery, indefinite-quantity contract meant to support work related to the Joint Polar Satellite System, NASA's Exploration, and In-space Services. The single-award contract has a five-year base performance period and a maximum ordering value of $719 million.

09:14 EDT Hippo names Peter Piotrowski Chief Claims Officer - Hippo named Peter Piotrowski, Chief Claims Officer. Piotrowski will lead claims for Hippo Insurance Services after serving as Chief Claims Officer at Vault for the last six years, and in executive roles at The Hanover Insurance Group, AIG and Chubb.

09:14 EDT Iveda Solutions awarded $1.7M contract expansion with Taiwan government agency - Iveda announces a newly signed contract with a government agency in Taiwan worth approximately $1.7M gross revenues. Through this contract, Iveda will provide networking equipment and interprocess communication computers to 45 new locations nationwide, assisting the agency in designing and installing a state-of-the-art video command, communication, and control system. All additional locations are anticipated to be completed by year end and will be overseen and managed by Iveda Taiwan. This project deployment has the potential for an additional 194 locations to be put under contract in the future, as there are a total of 300 locations countrywide. Iveda is unable to disclose the agency identity due to the sensitivity of the project confidentiality. According to Markets and Markets, the global video surveillance market is estimated to reach $76.4B by 2027 -- and Iveda is well positioned to follow alongside this upward trajectory.

09:11 EDT Blink Charging appoints Jenifer Yokley as SVP, global marketing - Blink Charging announced the appointment of Jenifer Yokley as Sr. Vice President of Global Marketing. In her position, Yokley will collaborate with Blink's executive team to provide overall vision and strategic leadership to all global marketing efforts and needs. She will help to realize Blink's goals by leveraging the strength of Blink's longevity in the market and its ability to develop products and services that meet the needs of businesses and drivers. Yokley will also focus on reinforcing Blink's position as an industry leader, ensuring the company capitalizes on its substantial growth by creating, implementing, and maintaining a clear, coordinated, and unique brand strategy aimed at both internal and external stakeholders. Prior to joining Blink, Jenifer served as Sr. Vice President of Marketing at a property technology provider, Allbridge, where she led marketing efforts with a strong focus on demonstrating a robust marketing return on investment.

09:08 EDT Bright Green selects test crops at Grants New Mexico facility - Bright Green Corporation announced that specific plants have now been selected for the test crops at its Grants New Mexico facility, and the company gives its operational updates. Revenue generation is planned to start late 2023 in our phase 1 greenhouse, with planned full production in the phase 1 greenhouse and the new construction of the phase 2 greenhouses starting in 2nd quarter 2024 and completion of phase 2 in late 2025. This complete build out will be the largest production and manufacturing facility of pharmaceutical grade cannabis extracts in the world. The company projects minimum debt and minimum share dilution to achieve these accomplishments through its previously disclosed $500 million EB-5 visa fundraising. The company expects and has these expectations by careful design to be the lowest cost, and highest quality producer of pharmaceutical cannabis in both dried flower and extract based applications for sales domestically and export to the European markets. The company has minimum debt, access to minimum dilution, no cost capital, and a proven best climate for cultivation these are facts the company has implemented in its plans. In 2019, the DEA announced steps to increase access to cannabis for research purposes. Bright Green was instrumental in shaping this new program and is authorized to utilize the company's Grants, New Mexico facility to produce high-quality cannabis intended for pharmaceutical and other product applications. As a DEA-approved project, the largest of its kind, Bright Green has partnered with Controlled Environment Agriculture Design, team of project managers, engineers, designers, and industry professionals who specialize in technical consulting services for the controlled environment agriculture industry. Thomas Larssen, President of CEAd, explained the two phases for the Grants facility: "Phase 1 of the project consisted of the retrofitting an existing high-tech 1 million sq ft. Dutch Venlo style glass greenhouse in a location with a well-suited climate for low-cost, high quality cannabis production. The interior has been removed and reconstructed from the ground up. It is important that each cultivar is provided a climate that fulfills the biological potential of the plant. We then ensure that the climate is maintained year-round, as batch-to-batch consistency in the chemotype during cultivation of the botanical raw material is critical. It is necessary to ensure the consistency of the chemical fingerprint of both the raw materials and the subsequent extracts are maintained to ensure consistent batch-to-batch quality, safety, and efficacy of the botanical drug products. Mr. Larssen added that "to help achieve the lowest possible cost of production, crop automation is used to avoid repetitive tasks and increase throughput." Phase 2 includes two additional highly automated greenhouses, each consisting of 57 acres for a combined 114 acres of production. "This is where things get high-tech with a fully automated benching system, the latest high-efficiency LED lighting, and the best in climate controls. This vision of the project funded by the EB-5 program: constructing the highest tech, highest density cannabis production possible all DEA, pharmaceutical grade and FDA compliant." The Company has contracted with two groups capable of providing the necessary chemovars while maintaining them in conditions completely free of pests and diseases such as Hop Latent Viroid. Nordic Supreme, based in Odense, Denmark, is a forward-thinking multi-disciplinary team consisting of breeders and researchers who are experts in production of unique cannabis varietals suitable for commercial greenhouse operations. As the Bright Green's market evolves and demand for specific molecules crystallizes, Nordic Supreme will be providing a breed program that supports increased production of select cannabinoids along with disease and pest tolerance or even resistance.

09:07 EDT GeoVax announces first patients vaccinated in Phase 2 trial of GEO-CM04S1 - GeoVax Labs announced that vaccinations have begun in an investigator-initiated clinical trial of GEO-CM04S1 in patients with chronic lymphocytic leukemia, CLL, being conducted at City of Hope National Medical Center. Despite a high vaccination rate, CLL patients may be at high risk for lethal COVID-19 infection due to poor immune response to currently available vaccines. The study is examining the use of two injections of GEO-CM04S1, three months apart, to assess immune responses in these vulnerable patients, with an mRNA vaccine as the control arm. Participants will be randomized 1:1 to receive two boosters with either the GEO-CM04S1 or the control vaccine. The primary immune response outcome will be assessed at 56 days following the first booster injection. David Dodd, GeoVax President and CEO, stated, "We are very pleased with the rapid start for this third important study for GEO-CM04S1, which we expect will achieve full patient enrollment within six months. We believe the GEO-CM04S1 vaccine, containing the two antigens, S and N, along with the recognized antibody and cellular immune responses resulting from the MVA approach, has the potential to offer greater booster protection than that from the current vaccines in use, as well as provide a greater degree of protection within immunocompromised patients. We expect the CLL trial will add to the data coming from our other ongoing trials, confirming the potential benefit of GEO-CM04S1 in another population of immunocompromised individuals. We look forward to sharing progress reports as we advance."

09:06 EDT Lionsgate says STARZ to exit Latin America by December 31 - Along with its earnings report last night, Lionsgate stated: "Subsequent to the end of the quarter, STARZ made a strategic decision to exit Latin America by December 31st and focus its operations on the U.S., U.K. and Canada."

09:04 EDT Fat Brands' Round Table Pizza opens three new locations in California - FAT Brands' Round Table Pizza has officially opened three new franchised locations in its home state of California. Located in San Luis Obispo, El Centro and Norco, these mark over 340 restaurants in the state since the opening of the very first Round Table Pizza location in Menlo Park nearly 65 years ago in 1959.

09:03 EDT Bank of Princeton authorizes new stock repurchase program - Bank of Princeton has adopted a new stock repurchase program. Under the 2023 stock repurchase program, management is authorized to repurchase up to 5% of the company's outstanding shares of common stock, with a total cost not to exceed $10.7M. 5% of the company's outstanding shares of common stock would be approximately 314,000 shares. Under the program, the company cannot purchase any shares unless the per share purchase price is less than the company's tangible book value per share. This repurchase program may be modified, extended or terminated by the Board of Directors at any time.

08:51 EDT Silo Pharma engages Clarivate for IP, patent management - Silo Pharma retained the services of Clarivate. Under terms of the agreement, Clarivate will manage, maintain, and track the Company's intellectual property assets and technology rights, and serve as an advisor for strategic IP and patent expansion in support of pipeline development. Silo Pharma engages in the acquisition, licensing, and development of intellectual property and technology rights from leading universities and researchers, including the use of psychedelic drugs. The Company's IP-protected portfolio assets were acquired through exclusive drug development collaborations including a sponsored study agreement and a licensing option agreement with Columbia University; a license and option agreement and an investigator-sponsored study agreement with the University of Maryland, Baltimore; a joint venture with Zylo Therapeutics, Inc.; and a sponsored research agreement with the University of California, San Francisco. Silo Pharma currently holds 3 issued and provisional patents with additional patent applications pending.

08:47 EDT AYRO launches educational webinar series - AYRO announces the launch of a new webinar series focused on the importance and value of low-speed electric vehicles, sustainability, and electric fleet management. The series will begin on August 17th, with a webinar covering the definition and benefits of LSEVs.

08:46 EDT Indaptus Therapeutics announces opening of next cohort in trial of Decoy20 - Indaptus Therapeutics announced completion of the first cohort of patients who received a single dose in Part 1 of its INDP-D101 trial of Decoy20 and the initiation of a new cohort following review of data by the Safety Review Committee as prescribed by the clinical trial protocol. Four patients were enrolled and evaluable in this cohort. Overall, patients experienced symptoms or adverse events that were short-lived and consistent with the mechanism of action of Decoy20. These symptoms included temperature elevation, nausea and chills. Additional transient effects included changes in heart rate and blood pressure. Three of the patients in the first cohort have completed the 28-day safety review period with two of the patients having also completed post-study tumor re-staging. One clinically relevant dose limiting toxicity of grade 3 bradycardia occurred and was reversible in under 30 minutes following a bolus of normal saline; grade 3 malaise in the same patient resolved overnight. Two patients experienced a grade 3 AST increase which resolved within 1 day. Other Adverse Events including chills, fatigue, vomiting, and fever were of grade 1-2 severity, resolved quickly, and were to be expected following exposure to the TLR4 agonist lipopolysaccharide (LPS), which is a major active ingredient of Decoy20 and a facilitator of innate and adaptive immune responses.

08:42 EDT SoundThinking announces launch of ResourceRouter Community. - SoundThinking announced the launch of ResourceRouter Community. This new application, tightly integrated with ShotSpotter, the leading gunshot detection solution, will support social service and community violence intervention organizations in their efforts to optimize their resource deployments, reduce violent crime, improve public safety and increase community trust. Miami-Dade Police Department in Florida will be among the first to deploy ResourceRouter Community as part of its holistic crime prevention strategy in partnership with Ummah Futures International, a community violence prevention organization and SoundThinking Data for Good partner. "We're thrilled to announce the launch of ResourceRouter Community," said Ralph Clark, CEO of SoundThinking, Inc. "This technology exemplifies the type of advanced, data-driven tools that make up the SafetySmart platform and expands SoundThinking's mission to create safer neighborhoods and save lives, beyond assisting law enforcement. We're proud to play a key role in fostering collaboration, empowering community organizations and protecting our cities."

08:40 EDT Chart Industries executes a MOU with 8 Rivers Capital - Chart Industries announced that it has executed a Memorandum of Understanding, MOU, with 8 Rivers Capital to evaluate 8 Rivers' portfolio of proprietary licensable technologies and processes and identify where Chart's technologies and systems can complement or bring added value to the 8 Rivers offerings. This collaboration includes developing equipment for 8 Rivers technologies backed up by Chart's decades of experience in the design and manufacture of cryogenic, compression and process technologies, to assist 8 Rivers in delivering a reliable and cost-effective solution to their customers. The companies will work together to identify and develop commercial opportunities to integrate Chart offerings into 8 Rivers projects. "We're looking forward to collaborating with 8 Rivers and building upon our combined expertise, in particular bringing our gaseous and liquid hydrogen solutions to our joint customers looking to achieve their net zero targets," stated Jill Evanko, CEO and President of Chart.

08:39 EDT Senti Bio, Celadon Partners announces transaction involving GeneFab - Senti Biosciences and Celadon Partners announced a transaction involving GeneFab, a new independent contract manufacturing and synthetic biology biofoundry focused on next-generation cell and gene therapies backed by Celadon Partners. In connection with the transaction, subject to satisfaction of certain conditions, Senti Bio is eligible to receive approximately $38 million in cash before the end of 2025. Approximately $18.9 million was due at closing, which was netted against an $18.9 million advance payment owed by Senti Bio to GeneFab for future manufacturing and support services. The remaining $18.9 million, subject to satisfaction of certain conditions, will be paid to Senti Bio in installments in 2024 and 2025. In addition, Senti Bio will receive $8 million in manufacturing credit, and will sublease its recently constructed 92,000 square foot current good manufacturing practice facility in Alameda, CA to GeneFab. With the additional non-dilutive capital and reduction of longer-term operating expenses, Senti Bio now believes its cash runway should extend into the fourth quarter of 2024. This transaction will enhance Senti Bio's focus on advancing its oncology programs into the clinic, and also enable GeneFab to support the manufacturing of a broad range of genetic medicines. Senti Bio expects a seamless technology transfer to GeneFab to support its clinical manufacturing needs. Simultaneous with this transaction, Philip Lee, Ph.D., Co-Founder and Chief Technology Officer of Senti Bio will depart from his position at Senti Bio and assume the role of Chief Executive Officer of GeneFab. Additionally, approximately 35% of Senti Bio's employees, which include experts in cell therapy chemistry, manufacturing, and controls, synthetic biology, and Gene Circuit development will transition from Senti Bio to GeneFab.

08:37 EDT Digital Ally announces several notable law enforcement agency orders - Digital Ally announced several notable law enforcement agency orders. These orders continue to demonstrate the Company's commitment to engineering innovative video solutions technology for law enforcement, first responders, private security and commercial fleets.Noteworthy subscription orders include products and services for the following departments: Currituck County Sheriff's Office: seventy-one FirstVu Pro body-worn cameras; Kosciusko County Sheriff's Office: forty FirstVu Pro body-worn cameras and three EVO HD in-car systems; Hannibal Police Department: forty-five FirstVu Pro body-worn cameras and ten EVO in-car systems; Rockwood Police Department: twelve FirstVu Pro body-worn cameras and twelve EVO in-car systems.

08:36 EDT Microbot Medical appoints Cornelis to scientific advisory board - Microbot Medical announces the expansion of its global team of experts supporting the Company as scientific advisory board members, SAB, with Francois Cornelis, MD, PhD joining Microbot's SAB. Professor Cornelis is an interventional radiologist who specializes in neuro interventions and image-guided minimally invasive therapies that allow for pain palliation and tumor control in the bones and spine.

08:35 EDT ABVC BioPharma regains compliance with Nasdaq's minimum bid price requirement - ABVC BioPharma announced today that on August 08, 2023, it received a letter from the Nasdaq Listing Qualifications Department notifying the Company that it had regained compliance with the minimum bid price requirement. On August 19, 2022, the Company received a notification that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days, as required by Nasdaq Listing Rules of The Nasdaq Stock Market.

08:34 EDT Evoke Pharma expects cash to fund operations into Q1 of 2024 - As of June 30, 2023, cash and cash equivalents were approximately $7.0 million. "We believe, based on our current operating plan, that our existing cash and cash equivalents, as well as future cash flows from net product sales of GIMOTI, will be sufficient to fund our operations into the first quarter of 2024," the company said.

08:32 EDT Workhorse Group encourages stockholders to vote FOR proposal - Workhorse Group mailed an infographic to shareholders ahead of the upcoming Special Meeting on August 28, 2023. The Company issued the following statement: "We are executing a clear strategy to stabilize, fix and ultimately grow Workhorse, and our earnings report this week demonstrated the important progress we are making. That said, we need to raise additional financing and to do so, we need our stockholders to vote FOR the proposal to increase the number of authorized shares of common stock. Our objective is to issue the shares we need to so we can fund the Company's operations; specifically, working capital, operating expenses, and capital expenditures. We encourage our stockholders to follow the recommendations of leading independent proxy advisors ISS and Glass Lewis, who both recommend that stockholders vote "FOR" the proposal. With your vote FOR, we can build a bridge to long-term growth and stockholder value creation, as we continue advancing our commercial EV roadmap, growing our Aero business and investing in our facilities and other initiatives."

08:30 EDT Arcutis, Huadong announce strategic collaboration, agreement for Roflumilast - Arcutis Biotherapeutics and Hangzhou Zhongmei Huadong Pharmaceutical Co, a wholly owned subsidiary of Huadong Medicine, announced that the companies have entered into a strategic collaboration and licensing agreement for the development, manufacture, and commercialization of topical roflumilast in Greater China and Southeast Asia. Huadong will receive an exclusive license for both the cream and foam formulations of topical roflumilast, a next generation phosphodiesterase type 4 inhibitor, for multiple dermatological conditions including plaque psoriasis, seborrheic dermatitis, and atopic dermatitis, and potentially additional dermatological conditions in the future. "This collaboration provides Arcutis access to the second largest pharmaceutical market in the world, providing an unparalleled opportunity to help individuals in this region suffering from immune-mediated skin diseases, and provides meaningful non-dilutive capital for us. With Huadong's deep dermatology and regional expertise, we are confident they are the ideal partner to develop and commercialize topical roflumilast for multiple dermatological indications in the Greater China and Southeast Asia markets," said Frank Watanabe, President and Chief Executive Officer, Arcutis. "This collaboration provides further validation of topical roflumilast's potential to be an effective and well-tolerated steroid-free treatment option for millions of people." Under the terms of the agreement, Arcutis will receive an upfront payment of $30 million, and an additional $64.25 million if certain regulatory and sales milestones are achieved. Arcutis is also eligible to receive tiered double-digit royalties.

08:28 EDT Ocean Biomedical provides latest updates on its broad programs - Ocean Biomedical shared an update on its broad range of promising programs in malaria, fibrosis, and multiple cancers. On September 14, 2023, Ocean Biomedical will host a Research and Development Day, featuring a live Q&A with its Scientific Co-founders. The research, breakthrough discoveries, and current undertakings of each of Ocean Biomedical's cancer, malaria, and pulmonary fibrosis programs are discussed in more detail below. Cancer Program. Updates on Ocean's late-stage preclinical work in oncology include: Recent results showing the effectiveness of anti-CHi3L1 in brain cancer, creating a 60% reduction in tumor growth in human glioblastoma multiforme stem cell model in vivo; Recent results showing major lung cancer tumor reduction of 85%-95% in primary lung cancer models of non-small cell lung cancer; Experimental results demonstrating Ocean's antibodies inhibit pulmonary metastasis, including malignant melanoma; and Extension of patent protections in the U.S. and overseas to cover potential treatments for multiple cancers, including breast cancer, prostate cancer, colon cancer, rectal cancer, ovarian cancer, kidney cancer, lung cancer, brain cancer, and skin cancer. Malaria Program. Recent updates include: Advancing understanding and control of the mechanisms by which Ocean's PfGARP antigen induces malaria parasite death; Optimizing and developing an mRNA vaccine candidate based on discoveries of PfGARP, PfSEA, and another antigen that may be able to simultaneously target the malaria parasite at different stages of the blood cycle, ideally for prevention in sub-Saharan Africa; Advancing a new therapeutic candidate for treating severe malaria; and Advancing a new therapeutic candidate for malaria prevention, ideally for use by tourists, business travelers, or in short-term deployment situations. Fibrosis Program. Progress includes: Testing Ocean's anti-fibrotic treatment candidate, "OCF-203," which has generated impressive reductions of fibrosis in multiple models and reduced collagen accumulation by 85%-90%; Experimenting with 'pale ear' mouse models, which have shown potential as a treatment candidate for Hermansky-Pudlak Syndrome, a rare disease that may hold potential for orphan drug designation; and Evaluating Ocean's anti-fibrotic treatment candidates' potential for use beyond IPF and HPS, with possible application in scleroderma, alcoholic liver disease, and non-alcoholic steatohepatitis.

08:25 EDT ZimVie announces FDA approval for Mobi-C implant - ZimVie announced that on August 1st, 2023, the U.S. Food and Drug Administration approved a smaller height of the Mobi-C Cervical Disc in seven footprints that will address the anatomical needs of the U.S. patient population. Physicians have used the market-leading Mobi-C device for cervical disc replacement at one level or two contiguous levels to treat patients in France since 2004 and in the U.S. since 2013 when it became the first cervical disc approved for one and two levels by the FDA.

08:24 EDT Wearable Devices to present Mudra wearable-AI technology at tinyML Talks - Wearable Devices is invited to present its Mudra Neural Input Interface technology at a webcast as part of the tinyML organization "tinyML Talks" on Tuesday, August 15, 2023 at 11:00 am ET. At the webcast, titled "Mudra: Reinventing Tiny Interfaces for Ubiquitous Digital Interaction," Leeor Langer, Chief Technology Officer of Wearable Devices, and Oleksandr Pirotskiy, Team Leader of Firmware Development of the Company, will present an hour-long presentation. The goal of the presentation is to share Wearable Devices' expertise in developing a neural input wristband for touchlessly interacting with spatial computing digital devices. The presentation will outline the capabilities of Surface Nerve Conductance bio-potential sensing, examine aspects of wrist neural data acquisition techniques, and explain classification methodologies employed for both embedded and mobile applications with the use of an Internal measurement Unit sensor. Special attention will be given to software integration within the Apple ecosystem.

08:22 EDT RumbleON lowers FY23 adjusted EBITDA view to $55M-$65M from $95M-$105M

08:21 EDT WillScot Mobile Mini expands portfolio, acquires Cold Box, A&M Cold Storage - WillScot Mobile Mini announced it has acquired Cold Box based in California and A&M Cold Storage based in Ohio. Tim Boswell, President and Chief Financial Officer, commented, "As space solutions experts, we specialize in providing value-added solutions that meet the most technically demanding needs for a wide variety of companies. The market for cold storage solutions is rapidly growing with powerful tailwinds across diverse end-markets such as manufacturing, pharmaceuticals, food service and distribution, retail, events, and many others. The addition of refrigerated storage capabilities to our fleet will give us the opportunity to deepen relationships with existing customers who manage temperature sensitive goods and materials and to expand within other growth markets. Cold storage solutions complement our value-added commercial approach, will leverage our unrivaled logistics and field service infrastructure, and will integrate seamlessly into our scalable operating platform. We are excited to welcome the Cold Box and A&M Cold Storage teams into WillScot Mobile Mini, as together we build upon their success to date and create the leading provider of temporary cold storage solutions in North America."

08:19 EDT Daxor announces letter in JACC-HF on heart failure trial with Daxor BVA-100 - Daxor Corporation announces a research letter in the Journal of the American College of Cardiology - Heart Failure, JACC-HF, reporting on the successful results of a pilot 31 patient randomized control trial conducted by the Duke Clinical Research Institute utilizing Daxor's BVA-100 diagnostic to measure clinician assessment accuracy and the impact of optimizing decongestion therapy for heart failure patients with the diagnostic. The study results showed that all patients had marked volume derangements, but that in over 68% of the cases care teams did not correctly diagnose the volume state of the patient by clinical exam when compared to BVA. Marat Fudim, M.D., principal investigator concluded, "Physician judgment of congestion status is not an accurate representation of actual blood volume. Our findings support the feasibility of randomized trials of BVA-guided heart failure therapy and our encouraging findings support a future, large, multicenter RCT to further investigate the effect of BVA measurement clinical outcomes." The study showed that utilizing the BVA-100 early in patient admission in the setting of a heart failure RCT was practical, but that optimization of the process would be part of a larger study trial design. Other measured outcomes such as patients in the control group being treated more effectively to an optimal volume, and being discharged after shorter lengths of stay were noted by researchers, but the findings did not reach statistical significance due to the small sample size of the study population.

08:18 EDT Vera Bradley announces collaboration with NFL - Vera Bradley has collaborated with The National Football League, NFL, on a three-year licensed product partnership. Vera Bradley's first-ever NFL collection includes officially licensed handbags, accessories, travel styles, and game-day essentials for fan-favorite teams. The collection is available to shop now, just in time for the 2023 NFL regular season. "We're proud to partner with the NFL to help Vera Bradley enthusiasts and football fans alike show their team spirit," noted Jackie Ardrey, CEO of Vera Bradley, Inc. "Women and girls make up 47% of the NFL fan base, and we're excited to make their game-watching experience even more fun by adding playful and approachable Vera Bradley style to game-day essentials."

08:17 EDT Third Harmonic Bio expects cash to fund operations through at least 2025 - Cash and cash equivalents totaled $278.1 million as of June 30, 2023. Based on the company's current operating plan, Third Harmonic Bio believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements through at least 2025.

08:15 EDT Molecular Templates announces upcoming milestones - Key Milestones for Molecular (MTEM) in 2023: accelerating enrollment across all clinical programs; Initiation of first-in-human Phase I study for MT-8421 in 3Q 2023; Advancement of Bristol Myers Squibb (BMY) research collaboration across multiple targets; MTEM expects to provide periodic updates on MT-6402, MT-8421, and MT-0169 throughout 2023.

08:12 EDT Cummins and Chevron announce MOU to leverage positioning in lower carbon fuels - Cummins (CMI) and Chevron (CVX), announced a memorandum of understanding to leverage complementary positioning in hydrogen, natural gas, and other lower carbon fuel value chains. The announcement expands the two companies' previous strategic collaboration on hydrogen and renewable natural gas and is expected to encompass other liquid renewable fuels, such as renewable gasoline blends, biodiesel and renewable diesel. This collaboration is intended to encourage commercial and industrial adoption in North America. "At Cummins, we are working to bring our Destination Zero strategy to life, and we recognize we can't do this alone," explained Jennifer Rumsey, President and CEO, Cummins Inc. "Through Accelera by Cummins we have leading zero-emissions technologies for commercial and industrial applications, and we continue to offer a broad portfolio of engine-based solutions that reduce greenhouse gas and other emissions today. By collaborating strategically with Chevron, we plan to improve access to fuel and infrastructure for our customers, helping grow the availability of alternative and renewable fuels while reducing emissions."

08:08 EDT CymaBay initiates Phase 3 study of Seladelpar - CymaBay announced the initiation of its 52-week, placebo-controlled, randomized, Phase 3 IDEAL study. The study aims to enroll 75 patients with PBC who have an incomplete response or intolerance to ursodeoxycholic acid in each case with ALP greater than the upper limit of normal but less than 1.67xULN, and total bilirubin less than or equal to 2xULN. Patients will be randomly assigned using a 2:1 ratio to oral, once daily seladelpar 10 mg or placebo. The primary outcome measure is the normalization of ALP at 52 weeks. Additional key outcomes evaluating efficacy include the percent change from baseline in ALP at 52 weeks and the level of self-reported pruritus at 6 months for patients with moderate to severe symptoms at baseline. PBC is a rare, chronic inflammatory liver disease primarily affecting women over the age of 40. PBC is characterized by impaired bile flow and the accumulation of toxic bile acids in the liver, leading to inflammation and destruction of the bile ducts within the liver and causing increased levels of ALP and total bilirubin.

08:06 EDT Genpact announces partnership with Heubach Group - Genpact announced its partnership with Heubach Group, a global supplier of comprehensive color solutions, to rapidly build, digitize and manage the finance, accounting, and supply chain processes of its newly combined company, following the successful acquisition of Clariant's global pigments business. Genpact has set up Heubach Group Business Services centers with fully optimized and agile operating models to provide superior customer experiences and fuel sustainable business growth.

08:05 EDT Candel Therapeutics announces anticipated 2023 milestones - Expect to announce additional clinical and immunological biomarker activity data from newly enrolled patients and additional follow-up on the 26 patients who received two injections of CAN-2409 in Cohort 2 of the phase 2 clinical trial of CAN-2409 plus valacyclovir combined with continued PD-(L)1 targeting agents in patients with late-stage NSCLC in Q3. Expect to announce initial overall survival and immunological biomarker data from the open-label, randomized phase 2 clinical trial of CAN-2409 plus valacyclovir combined with SoC for patients with borderline resectable pancreatic adenocarcimoma in Q4.

08:03 EDT Univar Solutions and Kalsec expand food ingredients distribution agreement - Univar B.V., a subsidiary of Univar Solutions, and Kalsec, a natural ingredient solution provider for the food and beverage industry, have expanded their food ingredients distribution agreement to include three additional European countries. The new agreement authorizes Univar Solutions to exclusively distribute Kalsec's natural taste & sensory, colors, and food protection ingredient solutions for savory applications in France, Belgium, and the Netherlands.

08:00 EDT Microbix Biosystems 'remains committed' to profitable growth model - The company said, "Microbix continues working to grow revenues across its business lines, and to improve gross margins to drive bottom-line results. Management remains committed to a profitable growth model, a goal that should be aided by the Agreement to advance Kinlytic to a successful re-launch into the U.S. market. Microbix continues working to grow revenues across its business lines, and to improve gross margins to drive bottom-line results. Management remains committed to a profitable growth model, a goal that should be aided by the Agreement to advance Kinlytic to a successful re-launch into the U.S. market."

07:47 EDT Jacobs to manage Inland Empire Utilities agency recycled water program - Jacobs was selected by Inland Empire Utilities Agency in California to provide program management, owners engineering services, and strategic funding advisory services for a major regional water management program that will incorporate indirect potable reuse to create a more sustainable, drought-resilient local water supply in the Chino Basin-one of the largest groundwater storage basins in southern California. The program encompasses a series of new integrated water infrastructure projects, including intra-basin recycled water conveyance, groundwater injection and replenishment and an advanced water purification facility that will be able to produce up to 15,000 acre-feet per year of purified water for indirect potable reuse using groundwater augmentation, enough water for nearly 100,000 residents. In addition to program management, Jacobs will provide owners engineering and specialist technology, design, permitting, community outreach and strategic advisory services for a range of projects that will deliver additional water into the basin.

07:45 EDT Bakkt sees FY23 cash flow usage $78M - $84M, down over 20% from previous view - Operating cash flow usage for full year 2023 expected to be $78M - $84M, down over 20% from previous guidance. Second half 2023 operating cash flow usage expected to be down over 75% from first half reflecting our focus on prudent expense management

07:43 EDT Rekor Systems launches Vehicle Insite application - Rekor Systems announced the launch of their Vehicle Insite application as part of its Rekor Discover platform - a breakthrough AI-driven roadway intelligence solution created to provide vehicle and business insights for brick-and-mortar organizations including shopping malls, hotels, theme parks, destination resorts, casinos, and more.

07:42 EDT WalkMe, Deloitte New Zealand enter strategic alliance - WalkMe announced it has entered into an alliance agreement with Deloitte New Zealand, a global leader in human capital and business transformation consulting. Deloitte is investing in a team in New Zealand to make technology adoption solutions broadly available to clients across the region. Together, WalkMe and Deloitte will help these organizations realize the rapid results that digital transformation strategies can deliver through efficient, effective, and sustained adoption of digital technologies.

07:41 EDT Mullen Automotive Class 3 vehicle production has begun - Mullen Automotive announces start of vehicle production at its Tunica, Mississippi, assembly plant for the Mullen THREE, Class 3 EV truck with first customer deliveries on track to begin in August and September. Mullen will be gradually ramping up production rate over the course of September through December. Once fully ramped, Class 3 production capacity at the Tunica facility is currently planned for 3,000 Class 3 vehicles per year. "I am proud to announce that our Class 3 vehicle line is now in production mode at our Tunica facility. Our team has been working seven days a week, day and night, getting this plant reconfigured and ready for Class 3 production," said David Michery, CEO and chairman of Mullen Automotive.

07:38 EDT AppTech Payments announces amendment of partnership with InstaCash - AppTech Payment announced the amendment of its Strategic Partnership Agreement with InstaCash. The amendment will extend InstaCash's mobile-to-mobile payment system license to Brazil and Mexico. "The extension of our agreement with InstaCash further reinforces AppTech's differentiated Fintech platform, as we continue to scale globally," said Luke D'Angelo, Chief Executive Officer of AppTech.

07:37 EDT ShockWave Medical to offer $500M convertible senior notes - Shockwave Medical intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2028 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Shockwave Medical also intends to grant the initial purchaser of the notes an option to purchase, within a 13-day period from, and including, the date on which the notes are first issued, up to an additional $75.0 million aggregate principal amount of notes. The notes will be senior, unsecured obligations of Shockwave Medical, and interest will be payable semi-annually in arrears. The notes will mature on August 15, 2028, unless earlier converted, repurchased or redeemed in accordance with the terms of the notes. Prior to 5:00 p.m., New York City time, on the business day immediately preceding May 15, 2028, the notes will be convertible at the option of holders of the notes only upon satisfaction of certain conditions and during certain periods, and thereafter, the notes will be convertible at the option of holders at any time until 5:00 p.m., New York City time, on the second scheduled trading day immediately preceding the maturity date, regardless of whether such conditions have been met. Upon conversion, Shockwave Medical will pay cash up to the aggregate principal amount of the notes to be converted and pay or deliver, as the case may be, cash, shares of Shockwave Medical's common stock or a combination of cash and shares of Shockwave Medical's common stock, at the election of Shockwave Medical, in respect of the remainder, if any, of Shockwave Medical's conversion obligation in excess of the aggregate principal amount of the notes being converted. Prior to August 20, 2026, the notes will not be redeemable. On or after August 20, 2026, and prior to May 15, 2028, Shockwave Medical may redeem for cash all or part of the notes, at its option, subject to a partial redemption limitation, if the last reported sale price of Shockwave Medical's common stock has been at least 130% of the conversion price then in effect for at least 20 trading days during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which Shockwave Medical provides notice of redemption. Holders of the notes will have the right to require Shockwave Medical to repurchase for cash all or a portion of their notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of a fundamental change. Shockwave Medical will also be required to increase, in certain circumstances, the conversion rate for holders who convert their notes in connection with certain fundamental changes occurring prior to the maturity date or convert their notes called for redemption following delivery by Shockwave Medical of a notice of redemption. The interest rate, initial conversion rate, offering price and other terms are to be determined upon pricing of the notes. Shockwave Medical intends to use a portion of the net proceeds from the offering to pay the cost of the capped call transactions, as described below. If the initial purchaser exercises its option to purchase additional notes, Shockwave Medical intends to use a portion of the net proceeds from the sale of the additional notes to enter into additional capped call transactions. Shockwave Medical intends to use the remainder of the net proceeds from the offering for general corporate purposes, which may include sales and marketing activities, medical affairs and educational efforts, research and development and clinical studies, and working capital, capital expenditures, and investments in and acquisitions of other companies, products or technologies in the future. However, Shockwave Medical has no commitments or specific plans with respect to any such investments in and acquisitions of other companies, products or technologies at this time. In connection with the pricing of the notes, Shockwave Medical expects to enter into privately negotiated capped call transactions with the initial purchaser of the notes or its affiliate and/or other financial institutions. The capped call transactions will cover, subject to anti-dilution adjustments substantially similar to those applicable to the notes, the number of shares of Shockwave Medical's common stock that will initially underlie the notes. The capped call transactions are expected generally to reduce the potential dilution to Shockwave Medical's common stock upon conversion of the notes and/or offset any cash payments that Shockwave Medical could be required to make in excess of the principal amount of any converted notes, as the case may be, with such reduction and/or offset subject to a cap to be equal to the cap price specified in the capped call transactions. In connection with establishing their initial hedges of the capped call transactions, the capped call counterparties have advised Shockwave Medical that they or their respective affiliates expect to enter into various derivative transactions with respect to Shockwave Medical's common stock and/or purchase shares of Shockwave Medical's common stock concurrently with, or shortly after, the pricing of the notes. This activity could increase the market price of Shockwave Medical's common stock or the notes concurrently with, or shortly after, the pricing of the notes.

07:35 EDT InflaRx expects cash to fund operations at least into 2026 - Cash, cash equivalents and marketable securities of EUR 115.2 million, expected to fund operations at least into 2026

07:32 EDT Supremex to continue to look for strategic acquisitions - The company said, "Since the beginning of 2023, new order intake has slowed appreciably as customers work through excess inventory built via over-ordering in a time of tight supply in 2022 and macro-economic conditions including rising interest rates and high inflation, which has adversely affected discretionary spending. The Company expects these conditions to affect its operations in the third quarter and potentially into the fourth quarter. Supremex will rely on its solid reputation and geographic reach to assist in mitigating a slowdown while continuing to tightly control expenses. The Company will continue to focus on integrating the Royal Envelope Corporation, Impression Paragraph Inc. and Graf-Pak business acquisitions, while actively seeking to capture all sales and cost synergies. As planned, Graf-Pak's operations have been merged into the Lachine facility and the Company continues to assess optimization initiatives to leverage Lachine's larger capacity. With respect to capital deployment for 2023, the Company will continue to look for strategic acquisitions, mainly in the Packaging and specialty products segment, while sustaining capital returns to shareholders."

07:26 EDT Super League partners with musical Hamilton, launches experience on Roblox - Super League (SLGG), in partnership with the musical Hamilton, announced the launch of the exciting new immersive experience Hamilton Simulator on Roblox (RBLX). "A once-in-a-generation cultural touchstone, Hamilton has expanded horizons and entertained legions of global fans, and now will be introduced to the massive global audience in the immersive world on Roblox," says Matt Edelman, President and Chief Commercial Officer for Super League. "We are grateful to the creators for allowing us to bring the music and majesty of Hamilton to an engaged and passionate community on such a powerful platform."

07:23 EDT KP Tissue sees Q3 Adjusted EBITDA similar to 2Q23 - The company said, "For the third quarter of 2023, as commodity and other input costs begin to decline, we will focus on maintaining our margins while also continuing to reinvest in the business to drive long-term value. Accordingly, Adjusted EBITDA in Q3 2023 is expected to be in the range of Q2 2023."

07:22 EDT Entrada Therapeutics appoints Chapman to its board of directors - Entrada Therapeutics announced the appointment of Gina Chapman to its Board of Directors, effective September 1, 2023. Ms. Chapman currently serves as President and Chief Executive Officer of CARGO Therapeutics. As President and CEO of CARGO Therapeutics, Chapman is leading the company's development of next-generation CAR T-cell therapies that address multiple mechanisms of resistance to deliver therapies to people living with cancer. Chapman joined CARGO in May of 2022

07:20 EDT Monte Rosa Therapeutics announces upcoming milestones - On track to present initial Phase 1/2 clinical data for MRT-2359 in MYC-driven solid tumors, including pharmacokinetics, pharmacodynamics, safety, and available initial efficacy data, in the second half of 2023; On track for planned IND submission for MRT-6160 in the first half of 2024; On track to nominate development candidates for one or more additional preclinical programs in the second half of 2023

07:19 EDT Werewolf Therapeutics expects cash to fund requirements through 4Q24 - As of June 30, 2023, cash and cash equivalents were $137.5 million, compared to $147.9 million as of March 31, 2023. The Company also had restricted cash and cash equivalents of $21.2 million as of June 30, 2023, and March 31, 2023, respectively. The Company expects that its existing cash and cash equivalents, together with anticipated collaboration revenue, will be sufficient to fund its operational expenses and capital expenditure requirements through at least the fourth quarter of 2024.

07:17 EDT Nkarta expects cash to fund operations into 2025 - Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into 2025.

07:15 EDT Tango Therapeutics announces $80M private placement financing - Tango Therapeutics (TNGX) has agreed to sell approximately 15.5 million shares of its common stock to a select group of institutional and accredited healthcare specialist investors in a private investment in public equity, PIPE, financing, at a per share price of $5.15. The financing is expected to close on Friday, August 11, 2023, subject to customary closing conditions. Gross proceeds from the private placement are anticipated to be approximately $80 million, before deducting any offering-related expenses. The financing was led by Nextech (NEXCF) with participation from Boxer Capital, Bain Capital Life Sciences, Casdin Capital, EcoR1 Capital, Southpoint Capital, Third Rock Ventures and a large institutional investor. "We are proud to have Nextech as a new investor, and to receive additional support from an outstanding group of current investors to further our mission to develop novel precision oncology treatments. This financing underscores the confidence in our near-term clinical programs, and our state-of-the-art target platform to discover and develop new drugs for people with cancer," said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics. "The additional funding strengthens our balance sheet at a time of strong momentum. Our two PRMT5 inhibitors are currently in dose escalation, and we recently demonstrated proof-of-mechanism for our lead program, TNG908. In addition, we have initiated the phase 1/2 clinical trial for TNG260, in combination with pembrolizumab in patients with checkpoint inhibitor resistant STK11-mutant cancers, and plan to initiate a fourth clinical trial in 2024."

07:14 EDT Gain Therapeutics expects cash to fund operations into Q3 of 2024 - Cash, cash equivalents and marketable securities were $16.2 million as of June 30, 2023, which the Company believes is sufficient to support operations into the third quarter of 2024.

07:13 EDT Optinose raises FY23 XCHANCE revenue view $64M-$70M from $62M-$68M - The Company expects XHANCE net revenues for the full year of 2023 to be between $64.0 to $70.0 million. Previously, the Company expected XHANCE net revenues for the full year of 2023 to be between $62.0 to $68.0 million. In addition, the Company continues to expect the full year 2023 XHANCE average net revenue per prescription to be approximately $200. The Company continues to expect total GAAP operating expenses for 2023 to be in the range of $88.0 to $93.0 million, of which the Company expects stock-based compensation to be approximately $6.0 million.

07:10 EDT Larimar Therapeutics expects cash to fund operations into 4Q24 - As of June 30, 2023, the Company had cash, cash equivalents and marketable securities totaling $104.2 million, which provides projected cash runway into the fourth quarter of 2024.

07:06 EDT Cabaletta Bio expects cash to fund operations through Q4 of 2025 - The Company expects that its cash, cash equivalents and short-term investments as of June 30, 2023, will enable it to fund its operating plan into the fourth quarter of 2025.

07:06 EDT TScan Therapeutics announces upcoming milestones - Heme Malignancies Program: Expects to reach the recommended Phase 2 dose for both TSC-100 and TSC-101 and report interim clinical data for the program by the end of 2023. Plans to complete Phase 1 dosing and report prevention of relapse data in 2024. Solid Tumor Program: Anticipates further expansion of the ImmunoBank with the recent filing of an IND for TSC-203-A0201, an HLA-A*02:01-restricted TCR targeting PRAME, and IND filings for two additional TCRs by year-end. Plans to initiate Phase 1 solid tumor clinical study in the second half of 2023 and anticipates sharing preliminary data by the end of 2023. Expects to report initial multiplexed therapy data for its first combinations of TCR-Ts under T-Plex, as well as response data for singleplex cohorts, in 2024.

07:02 EDT Eledon Pharmaceuticals announces upcoming milestones - Upcoming Anticipated 2023 Milestones: 3Q 2023: Begin enrollment in the Phase 2 BESTOW trial of tegoprubart in kidney transplantation. 4Q 2023: Report updated interim clinical data from the ongoing Phase 1b trial of tegoprubart in kidney transplantation.

06:57 EDT Capri Holdings will not hold Q1 earnings call - Due to the announcement of the transaction, Capri Holdings Limited will not hold its previously scheduled earnings call and will publish its financial results for the first quarter of fiscal 2024 after the market close today, August 10th, via press release. Capri Holdings expects to report revenue and earnings per diluted share for its first fiscal quarter 2024 slightly above its previously issued guidance range. Capri Holdings does not intend to provide a financial outlook moving forward.

06:52 EDT Dillard's sees FY23 CapEx $140M

06:52 EDT Tapestry to suspend share repurchase activity to prioritize de-leveraging - The company said, "Importantly, Tapestry has engaged with the rating agencies and is committed to a solid Investment Grade Rating. Tapestry will suspend its share repurchase activity to prioritize de-leveraging via debt reduction and anticipates reaching a leverage ratio of below 2.5x Debt/EBITDA within 24 months post-close. Furthermore, Tapestry is instituting a long-term leverage target of under 2.5x Debt/EBITDA."

06:51 EDT Tapestry to acquire Capri Holdings for $57.00 per share in cash - Tapestry (TPR) and Capri Holdings Limited (CPRI) have entered into a definitive agreement under which Tapestry will acquire Capri Holdings. Under the terms of the transaction Capri Holdings shareholders will receive $57.00 per share in cash for a total enterprise value of approximately $8.5B. This acquisition brings together six highly complementary brands with global reach, powered by Tapestry's data-rich customer engagement platform and diversified, direct-to-consumer operating model. The combined company generated global annual sales in excess of $12B with a presence in over 75 countries and achieved nearly $2B in adjusted operating profit in the prior fiscal year. The acquisition of Capri Holdings builds on Tapestry's core tenets as consumer-centric brand-builders and disciplined operators, accelerating its strategic and financial growth agenda. The combination: Unlocks Opportunity for Significant Cost Synergies: Expect to realize over $200M in run-rate cost synergies within three years post-closing, supported by operating cost savings and supply chain efficiencies; Generates Highly Diversified, Strong, and Consistent Cash Flow: Builds portfolio in durable, high-margin categories where Tapestry has best-in-class operational execution, enhancing strong and consistent cash flow; Generates significant cash flow that enables rapid deleverage, while continuing to reinvest in the business; Creates Path to Deliver Enhanced Total Shareholder Returns: Expected to deliver significant financial returns, including strong double-digit EPS accretion on an adjusted basis and compelling ROIC; Accretive to Tapestry's existing standalone TSR plan, underscoring the company's financial discipline and commitment to value creation; Continued commitment to capital return, with Tapestry's Board of Directors approving a 17% increase to its quarterly dividend per share, resulting in an anticipated payout of $1.40 per share or approximately $325M on in Fiscal Year 2024. The Boards of Directors of each of Tapestry, Inc. and Capri Holdings Limited have unanimously approved the transaction. The transaction is anticipated to close in calendar year 2024, subject to approval by the Capri Holdings shareholders, as well as the receipt of required regulatory approvals, and other customary closing conditions. The all-cash offer for Capri Holdings of $57.00 per share represents a premium of approximately 59% to the 30-day volume weighted average price ending August 9, 2023. The total enterprise value of the transaction of approximately $8.5B represents a 9x adjusted EBITDA multiple on a trailing-twelve-month basis, or 7x including expected synergies. The transaction is not subject to a financing condition. Tapestry has secured $8B in fully committed bridge financing from Bank of America N.A. and Morgan Stanley Senior Funding, Inc. The purchase price of approximately $8.5B is expected to be funded by a combination of senior notes, term loans, and excess Tapestry cash, a portion of which will be used to pay certain of Capri's existing outstanding debt. Importantly, Tapestry has engaged with the rating agencies and is committed to a solid Investment Grade Rating. Tapestry will suspend its share repurchase activity to prioritize de-leveraging via debt reduction and anticipates reaching a leverage ratio of below 2.5x Debt/EBITDA within 24 months post-close. Furthermore, Tapestry is instituting a long-term leverage target of under 2.5x Debt/EBITDA.

06:49 EDT Lazard reports preliminary AUM $244.4B as of July 31 - The month's AUM included market appreciation of $4.5B, foreign exchange appreciation of $1.7B and net outflows of $1.1B.

06:31 EDT Wolverine World Wide appoints Christopher Hufnagel as CEO - Wolverine World Wide has appointed Christopher Hufnagel, President of Wolverine, as President, CEO, and a member of the Board of Directors, effective immediately. Hufnagel succeeds Brendan Hoffman, who is no longer with the company. Hufnagel joined Wolverine Worldwide in 2008 and has served in leadership roles across the organization. Before his appointment as President in May 2023, he was President of the company's Active Group with responsibility for Merrell, Saucony, Chaco, the Kids Group, and Global Licensing. He has also served as Wolverine Worldwide's Global Brand President of Merrell and Global Brand President of CAT Footwear. In earlier roles at the company, he was President of Direct-to-Consumer and Senior VP of Strategy. Prior to joining Wolverine Worldwide, Hufnagel held senior leadership roles at Under Armour, Gap, and Abercrombie & Fitch.

06:11 EDT Novo Nordisk to acquire Inversago Pharma for up to $1.075B in cash - Novo Nordisk A/S and Inversago Pharma today announced that Novo Nordisk has agreed to acquire Inversago for up to $1.075B U.S. dollars in cash if certain development and commercial milestones are achieved. "Inversago Pharma is a private, Montreal-based developer of CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders. The acquisition of Inversago includes the company's lead development asset INV-202, an oral CB1 inverse agonist. INV-202 is designed to preferentially block the receptor protein CB1 - which plays an important role in metabolism and appetite regulation - in peripheral tissues such as adipose tissues, the gastro-intestinal tract, the kidneys, liver, pancreas, muscles and lungs. INV-202 demonstrated weight loss potential in a phase 1b trial and is currently in a phase 2 trial for diabetic kidney disease. Additional pipeline assets are also being developed for metabolic and fibrotic disorders. Novo Nordisk intends to investigate the potential of INV-202 for obesity and obesity-related complications," the company stated. "The acquisition of Inversago Pharma will further strengthen our clinical development pipeline in obesity and related disorders. This promising class of medicine pioneered by the Inversago team could lead to life-changing new treatment options for those living with a serious chronic disease and, in particular, may offer alternative or complementary solutions for people living with obesity," added Martin Holst Lange, executive vice president for Development at Novo Nordisk.

06:04 EDT ChipMOS reports July revenue $58.4M, down 5.7% - The company said, "The Company noted the sequential growth reflects the continued improvement in loading levels of its DDIC high-end test platform, and initial signs of improvement in its Memory business entering the second half of 2023."

05:16 EDT Royal Gold provides update on acquisition of Serrote, Santa Rita mines - Royal Gold announced that ACG Acquisition, or ACG, provided an update that ACG continues to discuss potential improvements to its transaction structure with its anchor investors and Appian Capital Advisory; ACG has not, however, reached agreement with the respective parties at this time; and if no agreement is reached, ACG's acquisition of the entities owning the Serrote and Santa Rita mines will not complete. In addition, ACG noted that the long-stop date to ACG's acquisition is August 18, 2023, after which either of ACG or Appian may terminate the acquisition agreement (unless the long-stop date is extended by mutual agreement). Royal Gold will provide an update as and when appropriate.